10th Translational Research Conference: Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis

Conference Details

Date: 16 October 2026

Time: 08:30

Duration: 3 days

Location: Dublin, Ireland

Cost: € 300 - € 600

Organiser: ESH - European School of Haematology

Conference Website

Conference Description

ABOUT THE CONFERENCE:

The ESH 10^th Translational Research Conference: Myelodysplastic Syndromes, Overlap MDS/MPN Disorders and Clonal Haematopoiesis will present the latest updates in some of the basic mechanisms of disease in MDS, MDS/MPN, and precursor conditions, and demonstrate how they are translated into clinical practice. Standards for treatment, timing and sequencing of treatment, and the latest clinical trial data and future directions for therapy will be discussed, along with interventions for clonal hematopoiesis precursor conditions.

Attendees will have the opportunity to learn practical approaches to treating these complicated diseases in a relaxed environment, with ample time provided for patient- and research centered questions, and for networking to create future clinical and research collaborations.

MAIN SCIENTIFIC TOPICS:

• Myelodysplastic Syndromes and the march of clonal haematopoiesis;
• The VEXAS nexus;
• Not another session on myelodysplastic syndromes classification and risk!
• Special Genetic Populations;
• Looking at myelodysplastic syndromes with a Crystal Ball;
• Treating Lower-risk myelodysplastic syndromes;
• Treating Higher-risk myelodysplastic syndromes;
• Transplantation;
• Academic clinical trials.

THE PROGRAMME WILL INCLUDE:

• Plenary Sessions;
• Panel Discussions;
• Simultaneous Meet the Expert Sessions;
• Poster Walks;
• Brief Oral Communications;
• Ample time for in-depth discussion.

LEARNING OBJECTIVES:

• Describe the basic mechanisms of disease in MDS, MDS/MPN, and precursor conditions;
• Demonstrate how the basic mechanisms of myeloid malignancies are translated into clinical practice;
• Describe the treatment approach for lower-risk MDS and MDS/MPN;
• Describe the treatment approach for higher-risk MDS and MDS/MPN.

For more information on this conference, please contact Stephen Soriano.